Printer Friendly

THE IMMUNE RESPONSE CORP., RHONE-POULENC RORER INC. AND PASTEUR MERIEUX CONNAUGHT GROUP ANNOUNCE DISCUSSIONS ON HIV MANUFACTURING JOINT VENTURE

THE IMMUNE RESPONSE CORP., RHONE-POULENC RORER INC. AND PASTEUR MERIEUX CONNAUGHT GROUP ANNOUNCE DISCUSSIONS ON HIV MANUFACTURING JOINT VENTURE
 SAN DIEGO and COLLEGEVILLE, Pa., Feb. 7 /PRNewswire/ -- The Immune Response Corporation (NASDAQ-NMS: IMNR), Rhone-Poulenc Rorer Inc. (NYSE: RPR) and Pasteur Merieux Connaught Group jointly announced today that they have begun discussions regarding the formation of a joint venture for the manufacture of clinical and commercial supplies of Immune Response's therapeutic vaccine for the treatment of Human Immunodeficiency Virus (HIV) infection. Immunization Products Limited, an existing joint venture between Immune Response and Rhone-Poulenc Rorer, is currently conducting a multicenter phase II/III clinical trial in the United States with the HIV therapeutic vaccine. This trial is scheduled for completion in 1992. The primary objective of this trial is to provide the data necessary to support a Product License Application planned for 1993 and to secure Food and Drug Administration approval for commercial marketing of the HIV therapeutic vaccine, while conducting additional studies designed to assess clinical endpoints. FDA approval must be obtained prior to marketing the HIV therapeutic vaccine in the United States.
 "We believe that the creation of a manufacturing joint venture will help assure adequate supplies to meet the needs for clinical and commercial quantities of the HIV therapeutic vaccine," stated Randy H. Thurman, president of Rhone-Poulenc Rorer Pharmaceuticals Inc.
 In connection with the proposed manufacturing joint venture, Rhone-Poulenc Rorer intends to construct a facility for the production of supplies for certain clinical studies beyond those in progress.
 Other aspects of the manufacturing joint venture under negotiation include the possible utilization of a Canadian facility owned by Pasteur Merieux Connaught for production of commercial supplies.
 Concurrently, Immune Response and Pasteur Merieux have begun discussions regarding renegotiation of the exclusive license agreement under which Pasteur Merieux has been granted development and marketing rights in certain countries outside North America. It is expected that certain of Pasteur Merieux's rights and obligations under the agreement may be transferred to a joint venture between Immunization Products Limited and Pasteur Merieux Connaught.
 The Immune Response Corporation is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection, which leads to AIDS, and for the treatment of certain autoimmune diseases, particularly rheumatoid arthritis, multiple sclerosis and insulin-dependent diabetes.
 Rhone-Poulenc Rorer Inc. is a global pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of human pharmaceuticals. RPR has annual sales of $3.8 billion and research expenditures of more than $440 million. The company operates in all major markets of the world.
 The Pasteur Merieux Connaught Group, a subsidiary of Institut Merieux and Rhone-Poulenc S.A. is a biological company applying immunology and molecular biology to improve human health through both prevention and treatment of infectious diseases and immunological disorders. Pasteur Merieux Connaught is the world's largest vaccine manufacturer, treating both infants and adults and also markets a wide array of immunoproteins. Pasteur Merieux Connaught is heavily engaged in the research and development of new products in various promising fields.
 -0- 2/7/92
 /CONTACT: Steven Basta of The Immune Response Corporation, 619-431-7080; or Jane Green of Rhone-Poulenc Rorer, 215-454-3871/
 (IMNR RPR) CO: The Immune Response Corporation; Rhone-Poulenc Rorer Inc.;
 Pasteur Merieux Connaught Group ST: California, Pennsylvania IN: MTC SU: JVN


JL-EH -- SD001 -- 8012 02/07/92 07:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 7, 1992
Words:552
Previous Article:SNO COUNTRY REPORTS OFFICIAL SKI REPORT FOR FEB. 7, 1992
Next Article:ST. MARTIN PRESS RESPONDS TO $150 MILLION LAWSUIT OVER WATERGATE EXPOSE
Topics:


Related Articles
THE IMMUNE RESPONSE CORPORATION COMMENTS ON INTEREST IN PROGRESS ON HIV THERAPEUTIC VACCINE
THE IMMUNE RESPONSE CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 1991 FINANCIAL RESULTS
THE IMMUNE RESPONSE CORP. CONFIRMS SCHEDULE FOR COMPLETION OF PHASE II/III CLINICAL TRIAL IN 1992
THE IMMUNE RESPONSE CORPORATION RECEIVES U.S. PATENT ON HIV TECHNOLOGY
THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC. COMMENCE ARBITRATION
RHONE-POULENC RORER FILES DEMAND FOR ARBITRATION IN ST. LOUIS, MISSOURI
THE IMMUNE RESPONSE CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 1994 FINANCIAL RESULTS
Corixa Announces Extension of Vaccine Adjuvant Research Agreement and Option Agreement With Pasteur Merieux Connaught
Corixa Announces Extension of Vaccine Adjuvant Research Agreement and Option Agreement with Pasteur Merieux Connaught (Rhone-Poulenc Group)

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters